Evidence map›Paper›PMID 35671096›Full record

ArticleThe Journal of clinical investigation2022

Upregulation of NKG2D ligands impairs hematopoietic stem cell function in Fanconi anemia.

José A Casado, Antonio Valeri, Rebeca Sanchez-Domínguez, Paula Vela, Andrea López, Susana Navarro, Omaira Alberquilla, Helmut Hanenberg, Roser Pujol, José-Carlos Segovia and 6 more

Open access · goldAbstract read
In one paragraph

Article in The Journal of clinical investigation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. MAIT Cells in the Bone Marrow of Patients with Aplastic Anemia.International journal of molecular sciences · 2024
    Article
  6. Management of Fanconi anemia beyond childhood.Hematology. American Society of Hematology. Education Program · 2023
    Review
  7. Does immune destruction drive all forms of bone marrow failure?The Journal of clinical investigation · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 2 countries.

José A CasadoDivision of Innovative Therapies, CIEMAT and Advanced Therapies Unit, IIS-Fundación Jimenez Diaz and Autónoma University, Madrid, Spain.
Antonio ValeriDivision of Innovative Therapies, CIEMAT and Advanced Therapies Unit, IIS-Fundación Jimenez Diaz and Autónoma University, Madrid, Spain.
Rebeca Sanchez-DomínguezDivision of Innovative Therapies, CIEMAT and Advanced Therapies Unit, IIS-Fundación Jimenez Diaz and Autónoma University, Madrid, Spain.
Paula VelaDivision of Innovative Therapies, CIEMAT and Advanced Therapies Unit, IIS-Fundación Jimenez Diaz and Autónoma University, Madrid, Spain.
Andrea LópezDivision of Innovative Therapies, CIEMAT and Advanced Therapies Unit, IIS-Fundación Jimenez Diaz and Autónoma University, Madrid, Spain.
Susana NavarroDivision of Innovative Therapies, CIEMAT and Advanced Therapies Unit, IIS-Fundación Jimenez Diaz and Autónoma University, Madrid, Spain.
Omaira AlberquillaDivision of Innovative Therapies, CIEMAT and Advanced Therapies Unit, IIS-Fundación Jimenez Diaz and Autónoma University, Madrid, Spain.
Helmut HanenbergDepartment of Pediatrics III, University Children's Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Roser PujolBiomedical Center for Research on Rare Diseases (CIBERER), Madrid, Spain.
José-Carlos SegoviaDivision of Innovative Therapies, CIEMAT and Advanced Therapies Unit, IIS-Fundación Jimenez Diaz and Autónoma University, Madrid, Spain.
Jordi MinguillónBiomedical Center for Research on Rare Diseases (CIBERER), Madrid, Spain.
Jordi SurrallésBiomedical Center for Research on Rare Diseases (CIBERER), Madrid, Spain.
Cristina Díaz de HerediaBiomedical Center for Research on Rare Diseases (CIBERER), Madrid, Spain.
Julián SevillaBiomedical Center for Research on Rare Diseases (CIBERER), Madrid, Spain.
Paula RioDivision of Innovative Therapies, CIEMAT and Advanced Therapies Unit, IIS-Fundación Jimenez Diaz and Autónoma University, Madrid, Spain.
Juan A BuerenDivision of Innovative Therapies, CIEMAT and Advanced Therapies Unit, IIS-Fundación Jimenez Diaz and Autónoma University, Madrid, Spain.
Centre for Biomedical Network Research on Rare Diseases · ESHospital de Sant Pau · ESHeinrich Heine University Düsseldorf · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fanconi anemia (FA) is the most prevalent inherited bone marrow failure (BMF) syndrome. Nevertheless, the pathophysiological mechanisms of BMF in FA have not been fully elucidated. Since FA cells are defective in DNA repair, we hypothesized that FA hematopoietic stem and progenitor cells (HSPCs) might express DNA damage-associated stress molecules such as natural killer group 2 member D ligands (NKG2D-Ls). These ligands could then interact with the activating NKG2D receptor expressed in cytotoxic NK or CD8+ T cells, which may result in progressive HSPC depletion. Our results indeed demonstrated upregulated levels of NKG2D-Ls in cultured FA fibroblasts and T cells, and these levels were further exacerbated by mitomycin C or formaldehyde. Notably, a high proportion of BM CD34+ HSPCs from patients with FA also expressed increased levels of NKG2D-Ls, which correlated inversely with the percentage of CD34+ cells in BM. Remarkably, the reduced clonogenic potential characteristic of FA HSPCs was improved by blocking NKG2D-NKG2D-L interactions. Moreover, the in vivo blockage of these interactions in a BMF FA mouse model ameliorated the anemia in these animals. Our study demonstrates the involvement of NKG2D-NKG2D-L interactions in FA HSPC functionality, suggesting an unexpected role of the immune system in the progressive BMF that is characteristic of FA.

Indexed as

Fanconi AnemiaAnimalsAntigens, CD34Hematopoietic Stem CellsLigandsMiceNK Cell Lectin-Like Receptor Subfamily KUp-RegulationAntigens, CD34LigandsNK Cell Lectin-Like Receptor Subfamily KBone marrowCellular immune responseHematopoietic stem cellsImmunologyStem cells

Identifiers

PMID35671096
PMCPMC9337828
OpenAlexW4281744016

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.